# Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

> **NCT06233942** · PHASE1 · RECRUITING · sponsor: **BeOne Medicines** · enrollment: 308 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** BG-C9074
- **DRUG:** Tislelizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06233942
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2027-09-28
- **Final completion:** 2028-05-15
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06233942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06233942, "Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06233942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*